




Enhanced PMCF

Ronald Rakos, PhD

The New EU Medical Device and IVD Regulations
August 29-30, 2017



A thick teal arc curves across the top and right side of the slide, starting from the left edge and ending near the bottom right corner.

Enhanced PMCF

PMS & PMCF - Articles 2 and 83

Article 2 Definitions – “post market surveillance”

all activities carried out by the manufacturers in cooperation with other economic operators to institute and keep up to date a systematic procedure to proactively collect and review experience gained from their devices placed on the market, made available on the market or put into service for the purpose of identifying any need to immediately apply any necessary corrective or preventive actions;

Post-market Surveillance System, Article 83

For each device the manufacturer shall plan, establish, document, implement, maintain and update a post-market surveillance system (risk based) PMS shall... actively and systematically gather record and analyze data on the quality performance and safety throughout the lifetime of the device

PMS & PMCF - Articles 83-86, Annex XIV, Part B

Post-market Clinical Follow-up (Annex XIV, Part B)

- PMCF shall be a continuous process that updates the clinical evaluation and shall address the post-market surveillance plan. PMCF shall proactively collect and evaluate clinical data from the use of the device (CE marked)... with the aim of confirming the safety and performance throughout the expected lifetime... ensuring continued acceptability of identified risks and detecting emerging risks on the basis of factual evidence.
- PMCF shall be performed according to the PMCF plan
- The PMCF plan shall specify methods/procedures for **proactively** collecting clinical data with the aim of...
 - confirm the safety and performance throughout the expected device lifetime
 - identify previously unknown side-effects and their monitoring
 - identify and analyze emergent risks

PMS & PMCF - Articles 83-86, Annex XIV, Part B

The PMCF plan shall include...

- references to relevant parts of the CER and Risk analysis
- objections of the PMCF
- an evaluation of the clinical data of equivalent or similar devices
- Reference to CS, harmonized standards as appropriate and guidance on PMCF
- detailed and **adequately justified time frame** for PMCF activities including the analysis of data and reporting
 - Often these timelines are excessively long; how can a PMCF study identify emerging risks if it does not start immediately?

The PMCF report shall contain the analysis of the findings and should be part of the CER and TF

The PMCF evaluation report shall be considered in the clinical evaluation and any preventative and/or corrective actions shall be implemented

Post Market Surveillance

QMS

PMS
Article 83

Vigilance
Article 87-90


Reactive PMS

Proactive PMS

PMCF
Annex XIV

PSUR
Article 86

SSCP
Article 32



Periodic Safety Update Report – Article 86

• **Article 86 – PSUR:**

- Conclusions of the benefit risk determination
- Main findings of PMCF
- Volume of Sales
- Estimate of the Population that use the device
- Where practicable usage frequency of the device

- Manufacturers of class IIb and III devices shall update the report at least annually.
- Manufacturers of class IIa devices shall update the report when necessary and at least every two years.
- Manufacturers of devices in class III **or** implantable devices shall submit reports by means of the electronic system to the notified body.

Technical Documentation on PMS – Annex III

Information



Plan



Report



Thank You!

